Rallybio CFO Jonathan I. Lieber exercises options

The options became fully vested and exercisable on October 26, three days before the reported exercises.

Available on EDGAR 11/02/2026 - 05:28 PM EST Accepted by SEC EDGAR 11/02/2026 - 05:27 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Rallybio Corp (RLYB) Chief Financial Officer Jonathan I. Lieber exercised options on October 29, 2026, acquiring 7,875 common shares at $14.88 per share and 13,589 common shares at $6.08 per share. The options’ vesting was accelerated in full, and they became fully vested and exercisable on October 26, 2026. No Rule 10b5-1 plan is reported.

Insider Trade Summary

21,464 shares exercised/converted

Exercise 4 txns

Insider Lieber Jonathan I

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Option (Right to Buy) F1	7,875	$0.00	$0.00
Exercise	Option (Right to Buy) F2	13,589	$0.00	$0.00
Exercise	Common Stock	7,875	$14.88	$117K
Exercise	Common Stock	13,589	$6.08	$83K

Holdings After Transaction: Option (Right to Buy) — 0 contracts (Direct); Common Stock — 37,015 shares (Direct)

Footnotes (2)

1. F1. The option is granted under the Company's 2021 Equity Incentive Plan. On October 26, 2026, the vesting of the option was accelerated in full, and the option became fully vested and exercisable as of that date.
2. F2. The option is granted under the Company's 2021 Equity Incentive Plan. On October 26, 2026, the vesting of the option was accelerated in full, and the option became fully vested and exercisable as of that date.

Key Figures

Options exercised: 7,875 options Exercise price: $14.88 per share Options exercised: 13,589 options +1 more

4 metrics

Options exercised 7,875 options Exercise on October 29, 2026; $14.88 exercise price per share.

Exercise price $14.88 per share Options exercised on October 29, 2026.

Options exercised 13,589 options Exercise on October 29, 2026; $6.08 exercise price per share.

Exercise price $6.08 per share Options exercised on October 29, 2026.

Key Terms

2021 Equity Incentive Plan, fully vested and exercisable, Option (Right to Buy)

3 terms

2021 Equity Incentive Plan technical

"granted under the Company's 2021 Equity Incentive Plan"

fully vested and exercisable technical

"the option became fully vested and exercisable"

Option (Right to Buy) financial

"Option (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did RLYB CFO Jonathan I. Lieber acquire through option exercises?

On October 29, 2026, Jonathan I. Lieber acquired 7,875 common shares at $14.88 per share and 13,589 common shares at $6.08 per share through option exercises. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lieber Jonathan I

(Last) (First) (Middle)

C/O RALLYBIO CORPORATION

PO BOX 325

(Street)

EAST BERLIN CONNECTICUT 06023

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rallybio Corp [ RLYB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/29/2026		M		7,875	A	$14.88	23,426	D
Common Stock	10/29/2026		M		13,589	A	$6.08	37,015	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to Buy)	$14.88	10/29/2026		M			7,875	(1)	02/15/2034	Common Stock	7,875	$0	0	D
Option (Right to Buy)	$6.08	10/29/2026		M			13,589	(2)	02/14/2035	Common Stock	13,589	$0	0	D

Explanation of Responses:

1. The option is granted under the Company's 2021 Equity Incentive Plan. On October 26, 2026, the vesting of the option was accelerated in full, and the option became fully vested and exercisable as of that date.

2. The option is granted under the Company's 2021 Equity Incentive Plan. On October 26, 2026, the vesting of the option was accelerated in full, and the option became fully vested and exercisable as of that date.

	By: /s/ Jonathan Lieber	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)